The U.S. Food and Drug Administration (FDA) has initiated a new pilot program, “PreCheck,” aimed at significantly accelerating the regulatory review process for new pharmaceutical manufacturing facilities within the United States. This initiative seeks to streamline the path for companies to bring new drug production sites online, potentially reducing approval timelines by over a year.

Seven companies have been selected as the inaugural participants in the PreCheck program: Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, and Kyowa Kirin. The program allows FDA regulators to begin evaluating new manufacturing facilities while they are still under construction, enabling early identification and correction of potential issues. This proactive approach is estimated to save companies up to 14 months in the traditional review process.

The selection criteria for the PreCheck program prioritized facilities capable of addressing market supply gaps or improving access to therapies for unmet medical needs. Many of the chosen participants, ranging from major pharmaceutical giants to specialized biotechs, are focused on producing complex biologic drugs or advanced genetic medicines. For instance, Eli Lilly’s new facility in Lebanon, Indiana, which will produce key ingredients for GLP-1 medications, and Regeneron’s $2 billion Saratoga Springs, New York, site, dedicated to biologics manufacturing, are both part of the program. Fujifilm Biotechnologies’ facility in Holly Springs, North Carolina, a contract manufacturer already producing monoclonal antibodies for clients like Regeneron and Johnson & Johnson, is also included.

The PreCheck program is structured with two main components: facility readiness, offering technical guidance before a site opens, and application submission, providing hands-on feedback, expedited inspections, and facility evaluations. This strategic move aligns with broader national efforts to bolster domestic drug production and enhance the resilience of the U.S. pharmaceutical supply chain.

Key Takeaways

• The FDA's new PreCheck pilot program aims to accelerate the regulatory review of new domestic pharmaceutical manufacturing facilities.
• Seven companies, including Eli Lilly and Regeneron, are the first participants, with the goal of reducing review times by up to 14 months.
• The program focuses on facilities addressing supply gaps or unmet medical needs, particularly those producing complex biologics and genetic medicines.

Editor’s Analysis & Impact

The FDA’s PreCheck program represents a significant policy shift designed to strengthen the domestic pharmaceutical supply chain and foster innovation. By expediting facility reviews, the initiative could dramatically reduce time-to-market for critical medicines, particularly complex biologics and gene therapies. This move is poised to benefit not only the participating companies by lowering development costs and accelerating revenue generation but also patients by improving access to essential treatments. The emphasis on domestic production aligns with national security interests, reducing reliance on foreign manufacturing. In the long term, this program could incentivize further investment in U.S. biomanufacturing, potentially creating a more robust and resilient healthcare infrastructure capable of responding to future public health crises and market demands.

Frequently Asked Questions

Q: What is the FDA PreCheck program?
A: The FDA PreCheck program is a new pilot initiative designed to accelerate the regulatory review process for new pharmaceutical manufacturing facilities in the United States, allowing the FDA to evaluate sites while they are still under construction.

Q: Which companies are participating in the initial phase?
A: The first seven companies selected for the program are Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, and Kyowa Kirin.

Q: What is the main benefit of the PreCheck program for pharmaceutical companies?
A: The primary benefit is the potential to save up to 14 months in the regulatory review timeline for new manufacturing facilities, enabling faster production and market access for critical drugs.